Knott David M Jr Acquires 75,058 Shares of Agios Pharmaceuticals, Inc. $AGIO

Knott David M Jr lifted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 417.0% in the first quarter, Holdings Channel.com reports. The institutional investor owned 93,058 shares of the biopharmaceutical company’s stock after acquiring an additional 75,058 shares during the period. Agios Pharmaceuticals comprises about 1.9% of Knott David M Jr’s holdings, making the stock its 15th biggest position. Knott David M Jr’s holdings in Agios Pharmaceuticals were worth $3,148,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. AQR Capital Management LLC boosted its stake in Agios Pharmaceuticals by 66.8% in the first quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company’s stock valued at $1,498,000 after buying an additional 20,625 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Agios Pharmaceuticals by 7.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company’s stock valued at $1,274,000 after acquiring an additional 2,920 shares during the last quarter. NewEdge Advisors LLC acquired a new position in Agios Pharmaceuticals during the first quarter worth about $40,000. Goldman Sachs Group Inc. raised its stake in Agios Pharmaceuticals by 16.1% during the first quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock worth $19,299,000 after acquiring an additional 91,482 shares in the last quarter. Finally, Woodline Partners LP bought a new position in shares of Agios Pharmaceuticals in the first quarter worth about $597,000.

Agios Pharmaceuticals Trading Up 0.6%

Agios Pharmaceuticals stock opened at $36.28 on Friday. The stock has a 50-day moving average price of $33.73 and a two-hundred day moving average price of $30.63. Agios Pharmaceuticals, Inc. has a 12 month low of $22.24 and a 12 month high of $46.00. The company has a market capitalization of $2.16 billion, a PE ratio of -5.00 and a beta of 0.54.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, topping the consensus estimate of ($1.81) by $0.12. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The company had revenue of $20.75 million for the quarter, compared to analysts’ expectations of $13.30 million. Agios Pharmaceuticals’s revenue for the quarter was up 137.7% on a year-over-year basis. As a group, analysts predict that Agios Pharmaceuticals, Inc. will post -6.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on AGIO. Truist Financial raised their price target on shares of Agios Pharmaceuticals from $36.00 to $41.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Bank of America upped their price objective on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. The Goldman Sachs Group increased their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research note on Wednesday, April 1st. JPMorgan Chase & Co. cut their target price on shares of Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a research report on Thursday, June 11th. Finally, HC Wainwright decreased their target price on shares of Agios Pharmaceuticals from $54.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $42.78.

Key Headlines Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $52 price target on Agios, while lifting multiple long-term earnings estimates for 2027–2030. The firm also published a note saying AGIO appears positioned to beat upcoming earnings expectations, which can support investor sentiment ahead of the Q2 report.
• Neutral Sentiment: The updated analyst forecast for FY2026 was slightly worse, with HC Wainwright trimming its EPS estimate, but the broader message remained constructive because the firm still expects profitability to improve over time.
• Negative Sentiment: Recent news that Agios scrapped the tebapivat sickle cell disease program continues to weigh on the stock. The company ended development after phase II data showed target engagement but not enough clinical differentiation, raising concerns about pipeline execution.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.